Monopar Therapeutics (NASDAQ:MNPR) Shares Up 10.3% – Time to Buy?

Posted by Geri Gentry on Jun 23rd, 2026

Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) shares rose 10.3% on Tuesday . The stock traded as high as $75.80 and last traded at $75.75. 57,507 shares were traded during trading, a decline of 72% from the average daily volume of 206,877 shares. The stock had previously closed at $68.66.

Analysts Set New Price Targets

MNPR has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Piper Sandler set a $105.00 price target on Monopar Therapeutics in a research note on Tuesday, June 2nd. BTIG Research restated a “buy” rating and set a $104.00 price objective on shares of Monopar Therapeutics in a report on Monday, February 23rd. HC Wainwright reiterated a “buy” rating on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Finally, Chardan Capital restated a “buy” rating and set a $100.00 price target on shares of Monopar Therapeutics in a report on Monday, March 30th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Monopar Therapeutics currently has an average rating of “Buy” and a consensus target price of $107.91.

Check Out Our Latest Analysis on MNPR

Monopar Therapeutics Trading Up 15.4%

The business has a fifty day moving average price of $59.89 and a two-hundred day moving average price of $61.79. The company has a market cap of $530.94 million, a price-to-earnings ratio of -41.71 and a beta of 1.52.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. On average, analysts anticipate that Monopar Therapeutics Inc. will post -2.82 EPS for the current year.

Institutional Trading of Monopar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics in the 3rd quarter worth about $28,000. BNP Paribas Financial Markets raised its holdings in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after buying an additional 349 shares in the last quarter. Sei Investments Co. raised its holdings in Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after buying an additional 656 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Monopar Therapeutics in the fourth quarter worth about $65,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Monopar Therapeutics in the fourth quarter worth about $86,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.